Hypereosinophilic syndrome · 10 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Alemtuzumab monotherapy Variant #03 | — | R 267 680 | 7d | ~15.0 mo | — | ~1 | ~R 267 680 PFS proxy · indirect | — |
Cladribine and Cytarabine Variant #01 | — | R 87 084 | 21d | — | — | ~3 | ~R 261 251 indirect | — |
Ruxolitinib monotherapy Variant #06 Partial | — | R 48 520 | — | — | — | ~1 | ~R 48 520 PFS proxy · indirect | 2 |
Benralizumab monotherapy Variant #01 | — | R 31 983 | 28d | — | — | ~7 | ~R 223 880 indirect | — |
Nilotinib monotherapy Variant #01 | — | R 28 002 | 28d | — | — | ~66 | ~R 1 848 148 indirect | — |
Imatinib monotherapy Variant #16 | — | R 1 401 | 28d | ~20.0 mo | ~53.0 mo | ~14 | ~R 19 610 PFS proxy · indirect | 8 |
Hydroxyurea monotherapy Variant #01 | — | R 265 | 28d | — | ~243.6 mo | ~2 | ~R 529 PFS proxy · indirect | — |
Peginterferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | — | — | ~4 | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Mepolizumab monotherapy Variant #01 Partial | — | — | 21d | — | — | ~8 | — | — |
10 of 10 regimens shown